Merve Hasanov is an Oncology physician affiliated with The Ohio State University. OpenAlex indexes 60 publications with 291 citations (h-index 7).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingIndustry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
1 company with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Real-world overall survival outcomes of lutetium (Lu <sup>177</sup> ) vipivotide tetraxetan treatment in prostate cancer.
Journal of Clinical Oncology
2026 - Single-cell characterization of renal cell carcinoma brain metastasis.
Journal of Clinical Oncology
2026 - Real-world toxicity outcomes with adjuvant pembrolizumab following nephrectomy for renal cell carcinoma.
Journal of Clinical Oncology
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Ernest Mazzaferri, MD
The Ohio State University
Jennifer Woyach, MD
The Ohio State University
Steven Gabbe, MD
The Ohio State University
Carl Leier, MD
The Ohio State University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”